Setback for AstraZeneca's much-hyped respiratory portfolio
This article was originally published in Scrip
Executive Summary
In a major setback for AstraZeneca's respiratory ambitions, its anti-IL-5 targeting monoclonal antibody failed to meet the primary endpoint in a Phase IIa trial in chronic obstructive pulmonary disease (COPD) as it did not reduce the acute exacerbation rate compared with placebo in the overall population. However Phase III testing of the product, which had already been initiated, is to proceed.